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Background: Airway inflammation is associated with an increased expression and release
of inflammatory reactants that regulate processes of cell migration, activation and
degranulation. The purpose of this study was to quantify bronchial lavage (BAL) fluid and
serum levels of chemokine (IL-8), secretory leukocyte protease inhibitor (SLPI), soluble
intracellular adhesion molecules-1 (sICAM-1) and sCD14, as surrogate markers of
inflammatory and immune response in asthma and chronic obstructive pulmonary disease
(COPD) patients with similar disease duration time.
Methods: Biomarkers in serum and BAL fluid from asthma (n ¼ 13) and COPD (n ¼ 25)
patients were measured using commercially available ELISA kits.
Results: We found that in asthma and COPD groups the concentrations of IL-8 and SLPI are
significantly higher in BAL fluid than in serum, while levels of sICAM-1 and sCD14 in BAL
fluid are significantly lower than in serum. Of these 4 measured biomarkers, only the
BAL IL-8 was higher in COPD patients when compared to asthma (Po0.05). In both groups,
BAL IL-8 correlated with SLPI (r ¼ 0.577, Po0.01 and r ¼ 0.589, Po0.05, respectively). In
patients with COPD the BAL sICAM-1 correlated with sCD14 (r ¼ 0.576, Po0.01), while
in asthma patients BAL sICAM-1 correlated with FEV1/FVC (r ¼ 0.418, Po0.01). Moreover,
in asthma patients the serum SLPI correlated with sCD14 (r ¼ 0.688, Po0.01) and serum
sICAM-1 negatively correlated with FEV1/FVC (r ¼ 0.582, Po0.05).
Conclusion: Our findings point to the importance of selecting a correct biological fluid
when analyzing specific biomarkers, and also show that of 4 measured biomarkers, only the
BAL IL-8 was higher in COPD patients when compared to asthma.
& 2007 Published by Elsevier Ltd.Published by Elsevier Ltd.
33 61 55; fax: +46 40 33 70 41.
e@med.lu.se (S.M. Janciauskiene).
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C. Hollander et al.1948Introduction that can reflect intensity of these pathological processesAirway inflammation is a cardinal pathophysiological feature
in patients with asthma and chronic obstructive pulmonary
disease (COPD). Both diseases are associated with an
increased expression and release of inflammatory reactants,
including cytokines, chemokines, proteases and their in-
hibitors, and adhesion molecules that regulate processes of
cell migration, activation and degranulation.1,2 Recent
studies show similar cellular responses in asthma and COPD,
with raised levels of neutrophils in more severe forms of
asthma3,4 and raised counts and activation of eosinophils in
COPD.5–7 Monocytes/macrophages are a significant compo-
nent of the inflammatory infiltrate in COPD8 and several
studies show that monocytes/macrophages are in an
activated state in asthma and orchestrate immune reac-
tions.9,10 For instance, levels of CD14, a marker of
monocyte/macrophage activation,11 have been shown to
be increased in asthma patients during acute asthma
attacks.12–14
IL-8 occurs at high levels in COPD and is a selective
attractant of neutrophils and IL-8 levels in induced sputum
are correlated with the extent of neutrophilic inflammation
and with disease severity (% predicted FEV1).
15,16 IL-8
has also been suggested to play a role in asthma, where
it is reported to be involved in lymphocyte, eosinophil
and basophil activation and migration to the inflammatory
site.
Adhesion molecules are important in the recruitment and
migration of leukocytes from circulation to the inflamma-
tory sites. Elevated cell surface expression of intercellular
adhesion molecule-1 (ICAM-1) has been demonstrated in
asthmatic airways17,18 and increased levels of soluble ICAM-1
(sICAM-1) has been found in asthmatic sputum.19 Whether
ICAM-1 is up-regulated to the same extent in COPD remains
uncertain, as the studies published so far have yielded
conflicting results.18–20
Proteases and their inhibitors are also implicated in the
pathophysiology and airway pathology of COPD as well as
asthma.21 Secretory leukocyte protease inhibitor (SLPI), also
known as antileukoprotease, is a naturally occurring serine
proteinase inhibitor produced by mucosal epithelial cells,
serous cells, and bronchiolar goblet cells in human air-
ways.22,23 Historically, this inhibitor was first purified from
lung secretions of patients with COPD and cystic fibrosis.
However, emerging evidence suggests that SLPI is also
important in the pathophysiology of asthma because it
exhibits broad-spectrum inhibitory activity against mast cell
and leukocyte serine proteases implicated in asthma
pathology.24–26
Thus, inflammation in the respiratory tract involves
epithelial cells, resident macrophages, eosinophils, and
neutrophils, and provides many cell-released markers that
can be used to follow pathophysiological changes related to
the disease. The majority of protein expression changes are
closely associated with many aspects of the pathophysiology
of disease, including inflammation, airway remodelling,
tissue damage and repair, mucus production, and plasma
infiltration.27 However, an understanding of the relationship
between the complex array of cells and mediators involved
in asthma and COPD is not yet fully dissected which makes
difficult to find a specific and sensitive panel of biomarkersand can help to predict the individual outcome. It is well
known that the validation of specific biomarkers requires
the choice of appropriate biological medium for analysis,
therefore we aimed to measure and to compare serum and
BAL fluid concentrations of SLPI, sICAM-1, IL-8 and sCD14 -as
potential inflammatory markers in asthma and COPD
patients.Materials and methods
Subjects
The studied group consisted of COPD (n ¼ 25) and asthma
(n ¼ 13) hospital outpatients, age 435 years from the
Department of Pulmonology and Immunology, Kaunas
Medical University Hospital, Lithuania. The COPD diagnosis
was based on the classification of the Global Initiative
for Chronic Obstructive Lung Disease (GOLD) criteria.28
Patients included in the study had a forced expiratory
volume in one second (FEV1) of o80% of predicted and a
FEV1/FVC (forced vital capacity) ratio ofo70% of predicted,
classified as moderate (n ¼ 13) to severe (n ¼ 12) COPD
(GOLD stages II–III). In to the study there were included
COPD patients with a smoking history (current or ex-smoker)
of X10 pack-years or never-smokers (n ¼ 4) who have
exposure to occupational dust and chemicals.
Adult asthmatics with a history of asthma of 6 months or
more were diagnosed according to the standards of the
Global Initiative for Asthma.29 All patients were steroid-
naı¨ve or without inhaled and systemic steroids for at least 1
month before the study. None of the subjects showed signs
of acute respiratory infection at least 1 month before the
investigation.
The exclusion criteria were a1-antitrypsin deficiency,
dyspnea of other origin (including cardiovascular disorders,
pneumonia, interstitial lung disease, pleural disease, upper
airways obstruction, neuromuscular disease and anaemia)
and bronchial carcinoma. Number of smoking pack-years
was calculated as the product of tobacco use (in years) and
the average number of cigarettes smoked per day/20
(year’s cig. per day/20). The study was approved at the
Regional Bioethics Committee (protocol no. 48/2004) and
written informed consent was received from all partici-
pants.Lung function testing
Pulmonary function was tested using a pneumotachometric
spirometer ‘‘Custo vitM’’ (Custo Med, Germany) with
subjects in the sitting position, and the highest value of
FEV1 and FVC from at least two technically satisfactory
maneuvers differing by less than 5% was recorded. Normal
values were characterized according to Quanjer.30 Subjects
had to avoid the use of long-acting b2-agonists for at least
48 h and short-acting b2-agonists for at least 8 h prior to the
test.
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Table 1 Patient demographics.
Diagnose Asthma COPD
Number of patients 13 25
Females/males 9/4 2/23
Age (years) 54.3711 6478.8




Never smokers 12 4
Smokers 1 10
Ex-smokers 0 11
BAL fluid recovery (ml) 79.8572.3 65.9272.11
BAL total protein (ng/ml) 62.9711.9 52.476.7
FEV1% of predicted
y 84.1725 58.3710
FVC% of predicted 91720 75717
FEV1/FVC% ratio 77.477.7 6079
All other data is presented as means7SD.
Data is presented as means7SE.
yMeasured after bronchodilatation.
Inflammatory markers in patients with COPD and asthma 1949Bronchoscopy and bronchoalveolar lavage
processing
Bronchoscopy was performed after the blood sampling and
lung function testing. Subjects were not allowed to drink or
eat at least 4 h prior the bronchoscopy. Smoking was not
allowed at least 10 h before the procedure. To perform BAL,
the local upper airways were anaesthetized with 5ml of 2%
Lidocaine (Grindex, Latvia). All bronchoscopic examinations
were performed in the morning. The bronchoscope (Olym-
pus, USA) was wedged into the segmental bronchus of the
middle lobe and 5 boluses of 20ml sterile saline solution at
37 1C was infused. Fluid was gently aspirated immediately
after the infusion had been completed and was collected
into a sterile container with a negative pressure of 40 to
50mmHg. The fluid was immediately filtered using 48 mm
nylon gauze (Millipore, North Ryde, NSW, Australia) and
centrifuged at 4 1C for 10min. Supernatants were removed
and frozen in Eppendorf tubes at 70 1C for further
investigation. All patients underwent bronchoscopic proce-
dures without any significant complication.
Serum samples
Blood samples were drawn in serum tubes, clotted at room
temperature for 30–60min and centrifuged for 10min at
3900 rpm. Serum samples were immediately frozen at
70 1C for further assay.
Analysis of serum and bronchial lavage (BAL) fluid
The serum and BAL fluid concentrations of IL-8, sICAM-1,
sCD14 and SLPI were determined using commercially
available quantitative enzyme-linked immunosorbent assay
(ELISA) kits (R&D Systems Minneapolis, USA) according to the
manufacturer’s instructions. Assays were performed in
duplicate and the optical density at 450 nm, with a back-
ground correction at 570 nm, was determined using a
microplate reader (Labsystems iEMS Reader MF). The read-
ings for each standard and sample were averaged and the
average of the zero standard was subtracted. The detection
limits of the IL-8, sICAM-1, sCD14-1 and SLPI kits were 31.2,
15.6, 125 and 62.5 pg/ml, respectively.
Analysis of total protein in BAL fluid
The protein concentration in the lavage fluids was measured
by Bradford protein assay according to manufacturer‘s
recommendations (Sigma, USA).31
Statistical analysis
Statistical analysis was performed using the SPSS software
(version 12.0.1 for Windows, SPSS Inc., Chicago, IL, USA).
Normal distribution of the variables was tested using the
Kolmogorov–Smirnov test and since log-transformation of
non-normally distributed variables did not improve the
normal distribution, non-parametric tests were used. The
Kruskal–Wallis test was used for comparisons between more
than two groups and if significance was reached, theMann–Whitney U test, with correction for multiple compar-
isons (Bonferroni), was used for group-wise comparisons.
Correlations were investigated using the Spearman rank
order correlation test. Data is presented as mean and range.
Results
Patient characteristics
Table 1 gives the demographic data, disease duration, lung
function and smoking habits of the investigated asthma and
COPD patients. The asthma patients were younger than the
COPD group (P ¼ 0.026), had more females than males
(69.2% vs. 8.7%, respectively) and included significantly
fewer smokers. Out of 25 COPD patients, 4 were never
smokers and 11 ex-smokers. As expected, COPD patients had
lower FEV1 (FEV1% of predicted 58.3 vs. 84.1, Po0.001)
compared to asthma patients. No significant difference was
found between asthma and COPD patients in disease
duration time (8.672.5 vs. 7.871.3 years), serum AAT
levels (1.4775.6 vs. 1.3875.4mg/ml) and the concentra-
tion of total BAL fluid proteins.
Concentrations of IL-8, SLPI, sICAM-1 and sCD14 in
BAL and serum
The concentration of BAL IL-8 was significantly higher in the
group with COPD than in the group with asthma (mean7SE:
0.10470.03 vs. 0.0370.01 ng/ml, P ¼ 0.04). No significant
difference was observed between the two groups in serum
IL-8 concentrations, although the mean levels were higher in
COPD than in the asthma patients (mean7SE: 0.0970.07 vs.
0.01670.01 ng/ml). In both groups IL-8 concentrations were
significantly higher in BAL fluid than in serum (COPD
P ¼ 0.011 and asthma P ¼ 0.034).
As shown in Table 2, we found no significant difference in
BAL and serum SLPI, sICAM-1 and sCD14 concentrations
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Table 2 Concentrations of measured variables in serum and BAL fluid.
Measured protein (ng/ml) COPD (n ¼ 25) Asthma (n ¼ 13)
Serum BAL Serum BAL
SLPI 40.34 (26.1–65)* 72.58 (0.4–250) 41.95 (28.6–60.1) 64.7 (17.9–116.8)
IL-8 0.09 (0.001–1.78) 0.104a (0.002–0.56) 0.016 (0.001–0.13) 0.03a (0–0.11)
sICAM-1 153 (92–224) 4 (0–15.3) 161 (102.4–314) 6.8 (0.9–14.4)
sCD14 1531 (750–2180) 363 (0–2667) 1433 (1065–1859) 292 (0.5–3091)
*Values are expressed as mean and (range).
aWelsh t-test shows significant difference in BAL IL-8 concentration between COPD and asthma patients t(28.3) ¼ 2.1, P ¼ 0.04.



















Serum Asthma – – – – – – – – –
IL-8 COPD – – – – – – – –
Serum Asthma – 0.688** – – – – –
SLPI COPD – – – – – 0.429* 0.408*
Serum Asthma – – – – – – – – 0.582*
ICAM-1 COPD – – – – – – – – –
Serum Asthma – 0.688** – – – – – – –
sCD14 COPD – – – – – – – – –
BAL Asthma – – – – – 0.589* – – –
IL-8 COPD – – – – – 0.577** – – –
BAL Asthma – – – – 0.589* – – – –
SLPI COPD – – – – 0.577**
BAL Asthma – – – – – – – – 0.418**
ICAM-1 COPD – – – – – – 0.576**
BAL Asthma – – –
sCD14 COPD – 0.429* – – – – 0.576** – –
Asthma – – 0.582* – – – 0.418** – –
FEV1/FVC COPD – 0.408* – – – – – –
**Correlation is significant at the 0.01 level.
*Correlation is significant at the 0.05 level.
–Non-significant.
C. Hollander et al.1950between the studied groups. However, SLPI concentration
was higher in BAL fluid compared to serum in both COPD
(72.6 vs. 40.3, statistically non-significant) and asthma (64.7
vs. 41.95, P ¼ 0.04) groups. In contrast, in both groups
levels of sICAM-1 and sCD14 in serum were higher compared
to BAL (COPD: 152.8 vs. 4 pg/ml, Po0.001 and asthma: 161
vs. 6.8, Po0.01) and (COPD: 1531 vs. 363.2 pg/ml, Po0.001
and asthma: 1433 vs. 292, Po0.01), respectively.Relationship between studied biomarkers in the
group with asthma and COPD
As shown in Table 3, in patients with asthma the serum
concentrations of SLPI significantly correlated with serum
sCD14 whereas the BAL concentration of SLPI correlated
with BAL IL-8 (r ¼ 0.589, Po0.05). Interestingly, FEV1/FVC
showed a negative correlation with serum concentration ofsICAM-1 (r ¼ 0.582, Po0.05), but a positive correlation
with BAL fluid sICAM-1 (r ¼ 0.418, Po0.05). In the group
with COPD, the BAL concentrations of IL-8 significantly
correlated with BAL SLPI and BAL concentrations of sICAM-1
correlated with BAL sCD14 (Table 3). In addition, negative
correlation was found between BAL concentration of sCD14
and serum SLPI (r ¼ 0.429, Po0.05) and positive correla-
tion between serum SLPI concentration and FEV1/FVC
(r ¼ 0.408, Po0.05). No association was observed between
measured biomarkers and smoking habit.Discussion
Previously it has been demonstrated that IL-8 levels are
increased in COPD patients,15,32 and that increased levels of
IL-8 in sputum samples correlate with the airway bacterial
load and proteinase released from activated neutrophils.33
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Inflammatory markers in patients with COPD and asthma 1951Recently, Schulz and collaborators34 have shown that in
subjects with COPD the constitutive and stimulated IL-8
release is significantly higher compared to ‘healthy’ smokers
and control subjects. Consistent with this, we also found
higher concentrations of BAL fluid IL-8 in the patients with
COPD than in those with asthma. It is important to note that
our patient groups differ significantly in age, gender, and
smoking habits; i.e. the asthma group includes predomi-
nantly never-smoking females while the COPD group is
primarily smoking males. Thus, it is possible that the higher
IL-8 levels in COPD patients are related to the above
differences between the patient groups. It has been
demonstrated that cigarette smoke induces the release of
IL-8 from cultured human bronchial epithelial cells,35 and
BAL specimens from non-asthmatic smokers have greater
concentrations of neutrophils, macrophages, and a number
of cytokines, including IL-1b, IL-6, IL-8, and monocyte
chemoattractant protein-1 than non-smokers.36 So far, the
differences and similarities in the pathological processes of
COPD patients with and without a smoking history are not
known. It is important to point out that 4 out of 25 COPD
patients included in our study were never smokers and 11
ex-smokers. However, we found no association between BAL
fluid or serum IL-8 levels and smoking history in the COPD
group, suggesting that the mechanism for IL-8 release may
depend on several factors, and not just simply on smoking
alone. Furthermore, the BAL IL-8 level did not correlate
with age and gender. The molecular mechanisms that
trigger, maintain, and regulate the expression and release
of IL-8 have not yet been fully elucidated. For instance,
bacterial endotoxin and tumor necrosis factor-alpha (TNF-a)
are known to increase IL-8 production by epithelial cells.37 It
has been proposed that neutrophil elastase may also
stimulate epithelial cells to produce more IL-8.38 Neutrophil
elastase has also been shown to increase SLPI transcription
in primary human airway epithelial cells,24,26 and we found a
direct correlation between BAL fluid IL-8 and SLPI concen-
trations in both COPD and asthma groups. However, SLPI,
like IL-8, may also be up-regulated by bacterial endotoxins
and cytokines such as IL-1 and TNFi.39,40
Inflammation in COPD and asthma extends beyond the
airways,41,42 therefore the biomarkers reflecting systemic
rather than local inflammation in the lungs may be of
greater value in diagnosis. In support of this, the results of
Little and collaborators43 show that high levels of plasma
intercellular adhesion molecule-1 (sICAM-1, CD54) and IL-8
in BAL fluid correlate with the development and severity of
chronic lung disease. Increased levels of sICAM-1 in plasma
and BAL from patients with COPD have been reported.44–46
Serum concentrations of sICAM-1 were also found to be
increased in acute asthma.47 We found no significant
difference in serum and BAL fluid sICAM-1 concentrations
between the COPD and asthma groups. However, it is
important to note that in patients with asthma the FEV1/
FVC ratio showed direct correlation with BAL sICAM-1 but
inverse correlation with serum sICAM-1. This finding is
difficult to interpret, but it has been shown that in
untreated asthmatics, ICAM-1 is over-expressed in bronchial
epithelial cells.18 The asthma patients included in our study
were untreated for at least 1 month prior to sample
collection and were in stable condition. This may explain
why sICAM-1 was found to be correlated to lung function inasthma patients. In the COPD group, BAL fluid sICAM-1
correlated with soluble sCD14, an acute phase protein,
mainly released from activated monocytes/macrophages
and hepatocytes.48 CD14-dependant mechanisms of inflam-
mation have been discussed in acute respiratory distress
syndrome,49 sarcoidosis50 and asthma.51 The soluble form of
CD14 is generated by proteolytic shedding of the membrane-
associated form (mCD14) during cellular activation and can
be detected proportionately in the BAL fluid.52 We found
significantly higher levels of sCD14 as well as sICAM-1 in
serum compared to BAL.
In general, many markers of inflammation in BAL fluid may
have a stronger signal than the same markers in blood and
vice versa, therefore the information gained from such
assays might be difficult to interpret. For instance, in the
present study we have found that in asthma and COPD
groups the concentrations of IL-8 and SLPI are significantly
higher in BAL fluid than in serum while levels of sICAM-1 and
sCD14 in BAL fluid are significantly lower than in serum. It is
well known that the major sites of SLPI synthesis are Clara
and goblet cells of the surface epithelium,53,54 and the
serous cells of the sub mucosal glands.55–57 Therefore, it is
reasonable to believe that analysis of serum SLPI may only
partially reflect the ongoing pathological process in the
airways, and therefore too insensitive to monitor the actual
state of disease. The relevance of circulating IL-8, sICAM-1
and sCD14 and their relation to locally production in COPD
and asthma remain much less clear. Thus, the applicability
of these biomarkers in respiratory diseases will much
depend on the selection of a correct biological fluid when
analyzing. Another important point, beside the compart-
ment, is the biological reasoning to measure the specific
biomarker. In order to avoid spurious association, the
selected biomarker must fit to the current knowledge of
the biochemical basis of the disorder.
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